Is TB-500 Legal in California? How to Access It Legally
HealthRX.com
No clear legal route to TB-500 in California is established
See the public record for TB-500
At a glance
- Federal approval / None; no FDA-approved product contains TB-500 [1]
- Compounding lists / Not listed among bulk substances eligible for pharmacy compounding [1][2][3][4]
- Safety-risk page / Sits in the 'nominated but withdrawn' table, not in active category 2 [7]
- Advisory committee / Voted July 23, 2026 to recommend adding it; advice only [8][5]
- HHS draft policy / Filed October 28, 2026; nonbinding, not an approval [5][6]
- Human data / No human study, no approved dose, no pharmacokinetic data [1]
- Anti-doping / WADA prohibits thymosin-beta4 and derivatives including TB-500 at all times [9]
What TB-500 actually is
TB-500 is a common name, not an official drug name, for a synthetic seven-amino-acid fragment of thymosin beta-4: residues 17 to 23, N-acetylated, molecular weight about 889 g/mol [1]. Full-length thymosin beta-4 is a 43-amino-acid protein found in blood, saliva, tears and wound fluid, and studies of the full-length protein do not show whether the fragment works [1]. FDA found several salts and derivatives, including different active moieties, sold under the same TB-500 name [1].
Is TB-500 approved by the FDA?
No. FDA's July 2026 review found no USP or National Formulary monograph for it, no FDA-approved drug containing it, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorised by the European Medicines Agency [1].
Can a pharmacy compound it?
A state-licensed pharmacy may compound with a bulk substance only if it complies with a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's list of bulk substances that can be used in compounding [4]. TB-500 meets none of those conditions and appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or on the list for outsourcing facilities (updated March 21, 2025) [2][3][4]. On FDA's safety-risk page it sits in the 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them; removal was not a finding that it is safe [7].
FDA staff proposed in July 2026 that neither TB-500 free base nor TB-500 acetate be added to the pharmacy bulks list [1]. The Pharmacy Compounding Advisory Committee voted in favour on July 23, 2026, against staff's recommendation; that is advice only, does not bind the agency, and adding a substance takes formal rulemaking [8][5].
HHS filed a draft enforcement-discretion policy on October 28, 2026 naming TB-500 among six peptides and covering TB-500 acetate by subcutaneous or intramuscular injection [5][6]. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician if the policy's conditions are met, for example a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and the label 'This is a compounded drug product. Not for resale.' [5][6]. Publication was scheduled for October 30, 2026, with comments due two weeks later [5]. The notice says it creates no rights and does not bind HHS or the public, and it does not approve TB-500 or place it on an FDA compounding list [5]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [5].
What about California?
The federal documents above address FDA and HHS policy, not California statutes or state pharmacy rules, so they do not say whether a California pharmacy or physician may supply TB-500. What they do establish is the federal position: no FDA-approved TB-500 product exists, TB-500 is not on the applicable federal bulk-compounding lists, and the only federal opening is the draft HHS policy for TB-500 acetate injections [1][2][3][4][5][6].
Athletes
WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, growth factors and growth factor modulators, prohibited at all times in and out of competition [9]. It appears on the 2026 List and remains on the 2027 List [9][10].
What is known about safety and dosing
There is no approved dose and no human dosing study of TB-500 [1]. FDA's adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and it found no published case reports [1]. FDA identified immunogenicity as a concern for injectable TB-500, potentially related to peptide aggregation and impurities, and found no nonclinical toxicity studies [1]. FDA's BPC-157 review describes a woman who used a research-use-only injectable product containing both BPC-157 and TB-500 and developed widespread skin and gum darkening within a week; because the product held two peptides, FDA said it cannot tell whether either caused it.
Frequently asked questions
Is TB-500 legal in California?
Can a state-licensed pharmacy compound TB-500 with a prescription?
Is TB-500 on the FDA safety-risk category 2 list?
Has TB-500 been tested in humans?
Is TB-500 banned in sport?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Are peptides legal to buy in California?
No clear legal route to TB-500 is established. The federal documents address FDA and HHS policy, not California statutes or state pharmacy rules, so they do not say whether California pharmacies or physicians may supply it.
How can I buy peptides legally?
No legal route is clearly established. A state-licensed pharmacy may compound a bulk substance only if it meets a USP or NF monograph, is part of an FDA-approved drug, or is on FDA's list of bulk substances, and TB-500 meets none of these. The only federal opening is a nonbinding HHS draft policy covering TB-500 acetate injections, which is not final.
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.